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SUMMARY. Much of our current understanding of
hepatits C virus (HCV) replication has hailed from the
use of a small number of cloned viral genomes and
transformed hepatoma cell lines. Recent evidence
suggests that lipoproteins play a key role in the HCV
life cycle and virus particles derived from the sera of
infected patients exist in association with host
lipoproteins. This report will review the literature on HCV
replication in primary hepatocytes and transformed cell
lines, focusing largely on host factors deﬁning particle
entry.
Keywords: hepatitis C, hepatocyte, internalization, lipopro-
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INTRODUCTION
Hepatitis C virus (HCV) is a positive stranded RNA virus
classiﬁed in its own genus, Hepacivirus, within the Flavi-
viridae family. Approximately, 170 million individuals are
infected with HCV worldwide. The acute phase of infection is
often subclinical with 70% of infected individuals developing
a chronic infection leading to progressive liver pathology.
The only established treatment is interferon-a, in combina-
tion with ribavirin, which is only partially effective, hence
there is an urgent need for the development of more effective
therapies. A full understanding of the pathogenesis of HCV
requires the availability of tissue culture models that sustain
viral replication and produce infectious particles. We will
review the literature utilizing primary hepatocytes to study
HCV infection and highlight commonalities and differences
with the increasing literature using transformed hepatoma
cell lines. This review focuses largely on viral entry and is
restricted in scope to recent developments.
Much of our current understanding of HCV replication has
been derived from the use of genomic replicons, which do
not allow viral entry or assembly to be studied (reviewed in
[1]). Dissection of HCV entry has been made possible using
HCV pseudoparticles (HCVpp) [2,3]. The recent discovery
that a genotype 2a strain of virus, derived from a Japanese
patient with a rare case of fulminant hepatitis and named
JFH-1, is able to replicate and release infectious particles in
cell culture (termed HCVcc) has allowed studies on the
complete viral life cycle [4–6]. Importantly, HCVcc is
infectious in chimpanzees and virus recovered from infected
serum remains infectious for hepatoma cells [7]. HCV
infection is limited to humans and chimpanzees, imposing
ethical, economic and technical limitations for in vivo
experimentation. Although transplantation of immunodeﬁ-
cient mice with human hepatocytes generates mice with
chimeric human livers which support HBV and HCV repli-
cation, allowing limited in vivo infection studies [8,9], the
majority of experiments to date have involved the infection
of cultured liver cells.
Techniques to study HCV entry have demonstrated the
involvement of at least three host cell molecules, the tetra-
spanin CD81 [10,11], scavenger receptor BI (SR-BI) [12–14]
and the tight junction protein family members Claudin-1, 6
and 9 (CLDN1, CLDN6 and CLDN9) [15–18]. Other mole-
cules implicated in HCV entry are the low-density lipoprotein
receptor (LDLr), Lipoprotein lipase [19], heparin sulphate
and the mannose binding lectins L-SIGN and DC-SIGN
(reviewed in [20]).
HCV and lipoproteins
There is increasing evidence that lipids and lipid receptors
are important in HCV infection. HCV isolated from patient
serum (HCVser) is associated with lipoproteins and entry
into hepatocytes has been suggested to involve lipid recep-
tors. The majority of infectious viruses in the peripheral
blood circulate in association with apolipoprotein B (ApoB)
and apolipoprotein E (ApoE) [21,22]. The buoyant density of
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over a range of densities from 1.03 to 1.25 g⁄mL with the
peak infectivity, as determined from animal challenge stud-
ies, in the lower density fraction(s). Extracellular HCVcc
particles have also been reported to have a heterogeneous
range of buoyant densities, with the lower density forms
representing very low-density lipoprotein (VLDL)-associated
particles [7,23,24]. Interestingly, HCVcc recovered from
infected animals displayed a lower buoyant density and
subsequent propagation of the virus in hepatoma cell lines
resulted in a transition to higher buoyant density [4,7].
Moreover, the speciﬁc infectivity of HCVcc recovered from
infected animals was higher than the input inocula, sug-
gesting that virus association with lipoproteins increases or
preserves the infectivity of low-density fractions.
Low-density lipoviral particles (LVP) containing core and
viral RNA have been reported to exist in association with
immunoglobulins and host triglyceride rich lipoproteins
[25]. More recently, the HCV envelope glycoproteins and
apolipoproteins ApoB, ApoE, ApoCII and ApoCIII have been
identiﬁed at the surface of LVPs [24,26]. Analysis of the lipid
composition of lipoproteins and of puriﬁed LVPs suggests
that LVPs are not simply aggregates of lipoproteins and viral
particles. Moreover electron microscopic investigation of
LVPs in plasma fractions corresponding to low-density lipo-
proteins (LDLs) show large spherical structures of 100 nm
diameter, whilst LDLs are more homogenous and of 25 nm
in diameter [25]. Andre et al. proposed that LVPs assemble
in the endoplasmic reticulum of hepatocytes, as opposed to
associating with lipoproteins in the circulation. The ability of
anti-ApoB antibodies to precipitate 50% of HCV RNA con-
taining particles from infected liver support this hypothesis
[27].
Recentreportshavehighlightedacriticalroleoflipoprotein
assembly and secretion in the HCV life cycle, where treatment
of hepatoma cells with a microsomal triglyceride transfer
protein (MTP) inhibitor or siRNA silencing of ApoB⁄E
expression reduced the levels of both VLDL and HCV in the
extracellular media, suggesting that viral secretion is depen-
dent on VLDL assembly and⁄or release [23,28,29]. Further-
more, HCVcc has been reported to replicate in cytoplasmic
membrane vesicles enriched with ApoB, ApoE and MTP,
proteins known to be required for the assembly of VLDL [29].
HCV infection of hepatocytes
Human hepatocytes are thought to be the primary target cell
supporting HCV replication in vivo. HCVpp entry into both
hepatocytes and Huh-7 hepatoma cells is pH-dependent
[3,30]. Studies to elucidate the involvement of clathrin in
HCVpp internalization have shown that Brefeldin A and
chloroprimazine treatment(s) signiﬁcantly reduce entry,
suggesting that viral entry is pH- and clathrin-dependent in
both cell types. However, establishing and maintaining cul-
tures of primary human hepatocytes (PHH) that sustain
HCVcc replication has proven difﬁcult. Hepatocytes support
only low levels of HCV replication, requiring PCR detection
of negative strand viral RNA to verify active replication
[5,31–34]. In contrast, immortalized human hepatocytes
have been reported to support HCV replication to higher
levels [35], however, this artiﬁcial system involves the cell
immortalization by HCV core prior to their electroporation
with full-length HCV RNA. Nevertheless, the authors report
viral replication and the detection of viral encoded proteins,
NS5A and E1, by immunogold labelling. Lazaro et al.
reported the successful HCVser infection of human fetal
hepatocytes (HFH), with the release of infectious virus in the
culture media that was able to infect naı ¨ve target cells [36].
HCVser infection of PHH has provided important insights
into how the virus may infect the liver [31,32], demon-
strating a role for CD81 and LDLr in infection. As previously
described for HCVcc infection of hepatoma cell lines [4,5],
anti-CD81 and soluble CD81 (sCD81) are both capable of
inhibiting HCVcc infection of PHH. In contrast, HCVser
infection of PHH could not be inhibited by sCD81, although
the virus remained sensitive to the neutralizing effects of
anti-CD81 antibodies. The ability to block infection of both
HCVcc and HCVser with anti-CD81 antibodies demonstrates
an important role of CD81 during infection of PHH and
hepatoma cell lines. Conversely, the inability of sCD81 to
neutralize HCVser infection suggests difference(s) between
particles isolated from patient serum and those generated in
cell culture. The authors suggest that particle-associated
lipoproteins may prevent E2 associating with CD81 and
prior interaction(s) of HCVser with cell surface molecules
prime CD81-dependent entry steps to occur. Several studies
have reported that anti-CD81 antibodies neutralize infec-
tivity after viral attachment to the target cell, consistent with
CD81 acting as a co-factor or internalization receptor [37–
39]. The inability of sCD81-sepharose to precipitate virus
from infected plasma is consistent with this model [40].
Current data support a model where E1E2 epitopes on
HCVser are masked by associated lipoproteins whilst these
epitopes are exposed on HCVcc particles. It is likely that
HCV binds the cell surface via glycosaminoglycans [41–44]
or lipoprotein receptors (LDLr/SR-BI) which lead to confor-
mational change(s) in the viral particle allowing the
engagement of CD81 and CLDN1 co-receptors.
Several reports have suggested that HCVser can bind cells
in an LDLr-dependent manner and that particle internali-
zation correlates with LDLr activity at the cell surface
[25,45]. Treatment of PHH with squalestatin and 25-
hydroxycholesterol to increase or decrease LDLr expression,
respectively, also implied an association between LDLr
expression and HCVser infection [31]. More signiﬁcantly,
antibodies speciﬁc for LDLr inhibited HCVser infection of
PHH, lending further support for a role of LDLr in HCVser
infection. A recent study analysed the binding of low-density
HCV fractions from a liver macerate to the HepG2 hepatoma
cell line [42]. Culturing cells in lipoprotein deﬁcient medium
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leading the authors to conclude that LDLr is the major
receptor deﬁning low-density HCV binding to cells [42]. In
contrast, LDLr is not required for HCVpp entry [3,12],
however, pseudoparticles are generated in 293T embryonal
kidney cells that do not produce VLDL and are therefore
unlikely to associate with lipoproteins and to mimic native
HCV.
Conversely, Maillard et al. reported that Chinese hamster
ovary cells engineered to over-express human scavenger
receptor BI (SR-BI) bind HCVser via the ApoB moiety of
VLDL [46]. SR-BI binds high density lipoprotein (HDL),
although it also recognises LDL, VLDL and oxLDL. Anti-
bodies speciﬁc for SR-BI have been reported to inhibit HCVcc
infection [13,39,47,48]. Exogenous HDL promotes HCVcc
and HCVpp infection via SR-BI [39,49–52] but has minimal
effect(s) on HCVser infection of PHH [31]. Discord between
HCVser and HCVcc interaction with SR-BI and LDLr may
simply reﬂect their differential association with lipoproteins.
However, some reports with HCVser measure virus binding
rather than productive replication, making deﬁnitive inter-
pretations of the in vivo relevance difﬁcult. In summary,
these data suggest that HCVser infection of hepatocytes is
dependent on lipoprotein receptors, lending further support
to the model that HCVser particles may differ signiﬁcantly
from HCVcc in their association with lipoproteins.
Sustained transmission of infectious HCV in HFH may
offer the closest model to viral replication in the liver
reported to date [36]. Lazaro et al. demonstrated HCV repli-
cation by quantifying viral genomes and by the detection
of viral encoded structural and non-structural proteins.
Whether transfected with HCV RNA or infected with
HCVser, HFH exhibit distinct ﬂuctuations in the amount(s) of
virus released, a trend that has also been observed in infected
chimpanzees and in HCVcc infected Huh-7.5 cells [4,7,36].
Infected HFHs demonstrate punctuate cytoplasmic NS3
staining in distinct areas or foci of infection, in agreement
with recent reports of HCVcc infected Huh-7.5 cells [53].
After 5 days, HFHs release virus particles of heterogenous
density with a major peak at 1.12 g⁄mL, however, by
40 days post-infection, the distribution was more homo-
genous and the peak of HCV RNA associated with a density
of 1.17–1.18 g⁄mL, comparable to serum-derived and
HCVcc particles. Electron microscopic examination of the
extracellular media identiﬁed virus like particles of 50–
90 nm in diameter that stained for E2 glycoproteins. This is
the ﬁrst report of hepatocytes supporting virus replication
where viral proteins can be visualized and the cells exhibit
some cytotoxicity following prolonged infection.
Receptor expression
The receptors that have been implicated in HCV infection are
not exclusively expressed within the liver. CD81 and CLDN1
are expressed in many tissues [54] although high levels of
CLDN1 are found within the liver [55]; SR-BI is present in
macrophages, steroidogenic and liver tissue [56]. Expression
of the recently described receptor molecules CLDN6 and
CLDN9 is also not restricted to the liver [16,18]. Hepatocytes
in tissue and ex vivo express CD81, CLDN1 and SR-BI, con-
sistent with their ability to support HCV infection [57]. The
lack of hepatocyte restricted expression of the three receptor
molecules suggests that their organization in hepatocytes
may be important for viral receptor activity or that addi-
tional receptor molecules await identiﬁcation. Our recent
studies using FRET methodologies to detect CD81-CLDN1
association demonstrated protein complexes at the plasma
membrane surface of both hepatocytes and Huh-7.5 hepa-
toma cells [58]. Receptor complexes were detected inde-
pendent of virus infection and the presence of CD81/CLDN1
co-receptor complexes does not indicate viral permissivity
[58].
Polarization
The discovery by Evans et al. that the tight junction protein
CLDN1 is a co-receptor for HCV highlighted the importance
of studying cellular polarity in HCV entry [15]. Tight Junc-
tions (TJs) are essential for establishing cell polarity and form
a barrier to regulate paracellular transport of solutes across
an epithelium. Hepatocytes are highly polarized, with their
plasma membranes being separated by tight junctions into
apical (canalicular) and basolateral (sinusoidal) domains
[59,60]. In culture, hepatocytes rapidly lose polarity due to
loss of tight junctional integrity, many methods are cur-
rently under investigation to promote and maintain hepatic
polarity in vitro (reviewed in [60,61]). Several studies have
been carried out to ﬁnd a way to keep the hepatocytes
isolated from normal liver in a well-differentiated and
polarized state. For example, hepatocyte culture on and in
various matrices can help to preserve their polarized func-
tional features [62]. Polarization in vitro is slow and variable
and as hepatocytes do not divide and differentiate their
ability to establish polarity is compromised. However, the
requirement of polarized cells and functional tight junctions
for HCV entry awaits conﬁrmation.
Mee et al. demonstrated that the epithelial cell line Caco-2,
which express CD81, CLDN1 and SR-BI, supported HCV
replication [63]. The viral receptors localized at the lateral
cell–cell junctions and disruption of TJs enhanced HCV
infection, suggesting that TJs may hinder viral access to
receptors expressed on the lateral and basolateral domains.
In Huh-7.5 hepatoma cells CD81 and CLDN1 co-localized
predominantly at intercellular junctions, however, these
cells were unable to form a barrier to solutes and disruption
of TJs had no effect on HCV infection or TJ protein locali-
zation, suggesting minimal polarization [58,60,63]. This is
in contrast to a recent report by Yang and colleagues [17],
demonstrating that Huh-7 cells had a low level trans-
epithelial resistance, consistent with polarization. These
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between different laboratories. Current data suggests that
functional TJs are not required for viral receptor activity and
polarization of the cell reduces CD81-CLDN1 association and
receptor activity (Mee & Harris, unpublished data). in vivo
HCV may target hepatocytes where cell–cell contacts
are damaged by inﬂammatory mediators or physical injury,
allowing more efﬁcient viral entry. This hypothesis
is supported by the high levels of viral replication observed
following liver transplantation, which may partly be a con-
sequence of liver damage during surgery [64]. It is important
to acknowledge that cultured PHH and Huh-7 cells exhibit
negligible markers of polarization [60], however, the
majority of hepatocytes in vivo will be polarized.
In polarized hepatocytes, the lipoprotein receptor SR-BI
functions as an endocytic receptor mediating the uptake of
lipoprotein cholesterol and secretion into bile [65]. Studies
using the WIF-B cell model for polarized hepatocytes dem-
onstrate SR-BI at the basolateral surface, ideally located for
binding of lipoproteins and virus from the sinusoidal blood.
Once the receptor is loaded with cholesterol, it transcytoses
to the bile canaliculi at the apical surface of the polarized cell
[66].
Earlier this year, we reported the co-localization of CD81
and CLDN1 at both the apical-canalicular and basolateral-
sinusoidal hepatocyte surface(s) [57], whilst SR-BI co-local-
ized with CLDN1 at the basolateral surface. FRET analysis
using receptor speciﬁc antibodies supported an association
between CD81 and CLDN1 in hepatocytes within human
liver tissue. These studies suggest that CLDN1 exists in both
tight junctional and non-junctional forms and, given the
highly permissive nature of non-polarized Huh-7 cells, we
suggest that HCV may preferentially utilise the non-junc-
tional forms of CLDN1 to enter cells.
CONCLUSIONS
The advent of HCVcc has enabled studies on the complete
viral life cycle and the next major challenge is to unify
observations made in different experimental systems with
the goal to deﬁne mechanisms of HCV tropism and replica-
tion in the infected host. It will be important to extend
current studies to include additional virus strains and
hepatic cells to ensure the validity of our observations. In the
absence of an immune competent small animal model that
allows for the application of reverse genetics, serum-derived
HCVcc recovered from infected animals will provide an
interesting source of virus that may mimic the virus-lipo-
protein complexes circulating in infected patients and will
replicate efﬁciently in vitro.
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